Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> exon 19 deletions or exon 21 mutations.

Winfree, Katherine B; Molife, Cliff; Peterson, Patrick M; Chen, Yongmei; Visseren-Grul, Carla M; Leusch, Mark S; Beyrer, Julie; Dimou, Anastasios

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations.

Winfree, Katherine B; Molife, Cliff; Peterson, Patrick M; Chen, Yongmei; Visseren-Grul, Carla M; Leusch, Mark S; Beyrer, Julie; Dimou, Anastasios.

Winfree KB; Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Molife C; Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Peterson PM; Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Chen Y; Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Visseren-Grul CM; Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Leusch MS; Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Beyrer J; Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Dimou A; Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

Future Oncol ; 17(22): 2867-2881, 2021 Aug.

Article en En | MEDLINE | ID: mdl-33866796

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas/mortalidad; Neoplasias Pulmonares/mortalidad; Inhibidores de Proteínas Quinasas/uso terapéutico; Adulto; Anciano; Carcinoma de Pulmón de Células no Pequeñas/diagnóstico; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Carcinoma de Pulmón de Células no Pequeñas/genética; Receptores ErbB/antagonistas & inhibidores; Receptores ErbB/genética; Exones/genética; Femenino; Estudios de Seguimiento; Humanos; Neoplasias Pulmonares/diagnóstico; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Masculino; Persona de Mediana Edad; Mutación; Estadificación de Neoplasias; Pronóstico; Supervivencia sin Progresión; Inhibidores de Proteínas Quinasas/farmacología; Estudios Retrospectivos

Palabras clave

exon 19 deletion; exon 21 (Leu858Arg) mutation; non-small-cell lung cancer; real-world evidence; tyrosine kinase inhibitor therapy

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Inhibidores de Proteínas Quinasas / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google